A Synthetically Accessible Small-Molecule Inhibitor of USP5-Cav3.2 Calcium Channel Interactions with Analgesic...

Area of Science:

• Neuroscience
• Pharmacology
• Molecular Biology

Background:

• Cav3.2 calcium channels are crucial for pain signaling and are upregulated in chronic pain conditions.
• Deubiquitinase USP5 stabilizes Cav3.2 channels, contributing to increased pain signaling.
• Previous research identified USP5's role in the aberrant expression of Cav3.2 channels.

Purpose of the Study:

• To identify and characterize novel inhibitors of the USP5-Cav3.2 interaction.
• To validate the therapeutic potential of a newly discovered rhodanine compound, II-1, in preclinical pain models.
• To explore the mechanism of action and specificity of II-1.

Main Methods:

• Compound library screening to identify inhibitors of USP5-Cav3.2 interaction.
• Biochemical assays to assess inhibition of protein-protein interactions and enzyme activity.
• Molecular docking to predict binding sites.
• Orthogonal assays and in vivo studies (formalin test, CFA-induced hyperalgesia, sciatic nerve injury model) to confirm efficacy and specificity.
• Utilized Cav3.2 null mice to confirm target engagement.

Main Results:

• A novel rhodanine compound, II-1, was identified that inhibits USP5-Cav3.2 interaction without affecting USP5 enzymatic activity.
• Molecular docking suggested distinct binding pockets at the USP5-Cav3.2 interface.
• Intrathecal II-1 administration reduced pain behaviors in formalin and CFA models and mechanical allodynia in a nerve injury model.
• The analgesic effects of II-1 were dependent on Cav3.2, as demonstrated in Cav3.2 null mice.

Conclusions:

• II-1 represents a novel class of analgesics targeting the Cav3.2/USP5 interface.
• The findings validate the Cav3.2/USP5 interaction as a therapeutic target for chronic pain.
• II-1 serves as a promising lead compound for developing structure-activity relationship studies and new pain therapeutics.